Last reviewed · How we verify
NCT03073902
The Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.
trial testing Liquid biopsy in NSCLC in 80 participants. Completed in 10 December 2018.
31 March 2018
Quick facts
| Lead sponsor | Xinqiao Hospital of Chongqing |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 25 March 2017 |
| Primary completion | 31 March 2018 |
| Estimated completion | 10 December 2018 |
| Sites | 1 location across China |
Drugs / interventions tested
- Liquid biopsy — full drug profile →
Conditions studied
- NSCLC — all drugs for NSCLC →
Sponsor
Xinqiao Hospital of Chongqing
Who can join
18 and older, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The detection of tissue PD-L1 immunohistochemistry in Non-small cell lung cancer (NSCLC) has an important role in guiding for the treatment of immune detection point. At the same time,tissue detection is time-consuming and laborious, liquid biopsy can reflect the information of tumor tissue,PD-L1 expression in serum and peripheral blood T cell are expected to be simple, rapid, non-invasive means of detection. The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum..The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum.By using variance analysis of repeated measures design information. Thus exploring the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum,guiding clinical practice of immunotherapy.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
Yang Q, Chen M, Gu J, Niu K, et al · · 2021 · cited 59× · PMID 33936103 · DOI 10.3389/fimmu.2021.665133 -
Liquid Biopsies: Emerging role and clinical applications in solid tumours.
Sisodiya S, Kasherwal V, Khan A, Roy B, et al · · 2023 · cited 21× · PMID 37327582 · DOI 10.1016/j.tranon.2023.101716 -
Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non-Small-Cell Lung Cancer.
Zhao X, Li J, Zheng L, Yang Q, et al · · 2022 · cited 8× · PMID 35141280 · DOI 10.3389/fmolb.2022.786864
Verify or expand the search:
- PubMed search for NCT03073902
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liquid biopsy
Trials testing the same drug.
- NCT06605443 — Precision Medicine for L/GCMN and Melanoma 2 · recruiting
- NCT06283576 — Pancreatic Cancer Initial Detection Via Liquid Biopsy · enrolling by invitation
- NCT06592716 — Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples? · active not recruiting
- NCT07418125 — Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA · NA · recruiting
- NCT06605417 — Understanding the Transition from Normal Melanocytes to Nevus to Melanoma · recruiting
Other recruiting trials for NSCLC
Currently open trials in the same condition.
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting
Other Xinqiao Hospital of Chongqing trials
Trials by the same sponsor.
- NCT07347626 — Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis · Phase 3 · not yet recruiting
- NCT07349836 — Application of mRNA Immunotherapy Technology in EB Virus Related Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07362758 — Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07349849 — Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies · EARLY_PHASE1 · recruiting
- NCT06987305 — Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03073902 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xinqiao Hospital of Chongqing
- Last refreshed: 28 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03073902.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing